Cargando…

Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders

BACKGROUND: Hyperphosphatemia in chronic kidney disease (CKD) patients is often treated with calcium carbonate (CaCO3) despite the fact that CaCO3 is associated with increased calcium load and potentially increased cardiovascular risk. Alternative treatments with noncalcium-based phosphate binders d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goh, B. L., Soraya, A., Goh, A., Ang, K. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169205/ https://www.ncbi.nlm.nih.gov/pubmed/30327732 http://dx.doi.org/10.1155/2018/2138528

Ejemplares similares

Effects of calcium-containing phosphate binders on cardiovascular events and mortality in predialysis CKD stage 5 patients
por: Tsai, Ping-Huang, et al.
Publicado: (2020)

Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia
por: Nitta, Kosaku, et al.
Publicado: (2023)

The demise of calcium-based phosphate binders—is this appropriate for children?
por: Rees, Lesley, et al.
Publicado: (2014)

Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations
por: Chaiyakittisopon, Kamolpat, et al.
Publicado: (2021)

Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model
por: Brunelli, Steven M., et al.
Publicado: (2017)

Phosphate intake, hyperphosphatemia, and kidney function
por: Rubio-Aliaga, Isabel, et al.
Publicado: (2022)

Comment on: “Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode”
por: Rascati, Karen
Publicado: (2017)

Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia
por: Wilson, Rosamund J, et al.
Publicado: (2017)

Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review
por: Fishbane, Steven N., et al.
Publicado: (2021)

Phosphate-Trapping Liposomes for Long-Term Management of Hyperphosphatemia
por: Tzror-Azankot, Chen, et al.
Publicado: (2022)

Effectiveness and cost-efficiency of phosphate binders in hemodialysis
por: Fröschl, Barbara, et al.
Publicado: (2009)

Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
por: Negri, Armando Luis, et al.
Publicado: (2015)

Calcium-based phosphate binder use is associated with lower risk of osteoporosis in hemodialysis patients
por: Hashimoto, Hiroko, et al.
Publicado: (2021)

Associations of Calcium from Food Sources versus Phosphate Binders with Serum Calcium and FGF23 in Hemodialysis Patients
por: Mahdavi, Sara, et al.
Publicado: (2019)

Tmem174, a regulator of phosphate transporter prevents hyperphosphatemia
por: Sasaki, Sumire, et al.
Publicado: (2022)

Dual-Energy Computed Tomography Virtual Noncalcium Technique in Diagnosing Osteoporosis: Correlation With Quantitative Computed Tomography
por: Liu, Zhenghua, et al.
Publicado: (2021)

Assessment of thoracic disk herniation by using virtual noncalcium dual-energy CT in comparison with standard grayscale CT
por: Koch, Vitali, et al.
Publicado: (2021)

Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis
por: Wang, Yong, et al.
Publicado: (2015)

Optimal predialysis care
por: Sijpkens, Yvo W. J., et al.
Publicado: (2008)

Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients
por: Nguyen, Hai V., et al.
Publicado: (2016)

Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
por: Scaria, P. Thomas, et al.
Publicado: (2009)

Hyperphosphatemia and Cardiovascular Disease
por: Zhou, Chao, et al.
Publicado: (2021)

Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
por: GAO, ZHUO, et al.
Publicado: (2013)

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data
por: Rodby, Roger A., et al.
Publicado: (2015)

Patient education for hyperphosphatemia management: Improving outcomes while decreasing costs?
por: Karavetian, Mirey, et al.
Publicado: (2018)

Antibody‐mediated inhibition of EGFR reduces phosphate excretion and induces hyperphosphatemia and mild hypomagnesemia in mice
por: Ortega, Bernardo, et al.
Publicado: (2017)

Pharmacology of the Phosphate Binder, Lanthanum Carbonate
por: Damment, Stephen JP
Publicado: (2011)

Diagnostic accuracy of color-coded virtual noncalcium reconstructions derived from portal venous phase dual-energy CT in the assessment of lumbar disk herniation
por: Koch, Vitali, et al.
Publicado: (2021)

Association of physical function with predialysis blood pressure in patients on hemodialysis
por: Abreo, Adrian P, et al.
Publicado: (2014)

Review of predialysis education programs: a need for standardization
por: Van den Bosch, Judith, et al.
Publicado: (2015)

Preparation of acid aluminum phosphate solutions for metakaolin phosphate geopolymer binder
por: Yankwa Djobo, Jean Noël, et al.
Publicado: (2021)

Effect of Intradialytic Exercise on Hyperphosphatemia and Malnutrition
por: Salhab, Nada, et al.
Publicado: (2019)

Control of hyperphosphatemia and maintenance of calcemia in CKD
por: Carvalho, Aluizio Barbosa, et al.
Publicado: (2021)

Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?
por: Mudge, David W, et al.
Publicado: (2011)

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide
por: Cernaro, Valeria, et al.
Publicado: (2016)

Interventional study to improve adherence to phosphate binder treatment in dialysis patients
por: Hjemås, Bodil Jahren, et al.
Publicado: (2019)

Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients
por: Lenglet, Aurélie, et al.
Publicado: (2013)

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015)

Nutritional Guideline for the Management of Mexican Patients with CKD and Hyperphosphatemia
por: Palafox-Serdán, Frida, et al.
Publicado: (2020)

Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients
por: Farrand, Kimberly F, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9rc81uis6v5ds5gs4ditrtvag1